October 2, 2022 | Targeted Therapies in Oncology

ESMO 2022: New Combinations and Settings in RCC Show Mixed Results

October 19, 2022

Clinical Articles

Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.

Excitement Shown With New NCI Director But Uncertainty Looms at Launch of the ARPA-H Institute

October 19, 2022

Clinical Articles

The oncology community has enjoyed success to a large degree through the existing NIH and NCI mechanisms. Will they ask how can they work with us in a concerted fashion to benefit new discoveries, novel translation in well-designed clinical trials, and eventual development of exciting, more effective cancer therapies for patients?